NASDAQ: IPA - ImmunoPrecise Antibodies Ltd.

Rentabilidad a seis meses: -59%
Rendimiento de dividendos: 0.00%
Sector: Healthcare

Calendario de promoción ImmunoPrecise Antibodies Ltd.


Acerca de la empresa ImmunoPrecise Antibodies Ltd.

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes. The company also offers syngeneic cell line for immunization and screening; and peptide production for subsequent antibody discovery campaign.

más detalles
In addition, it provides B cell select platform which allows for the interrogation of animal antibody repertoire; screening of the immune repertoire of rabbits and chickens and select the desired antibody directly from the B cells; single step hybridoma, a semi-solid media to grow mouse and rat hybridomas; and DeepDisplay, a combination of transgenic animal platform and custom IPA phage display antibody selection. The company also offers phage display, a custom immune libraries from multiple species; and CAR development, an adaptable antibody which allows the inclusion of functional data early in the screening funnel. Further, it provides silico developability, a profiling toolset for antibody lead candidates; and vitro analytical tools for the study of various critical quality attributes. Additionally, the company offers LucinaTech, an antibody humanization to identify essential framework and CDR residues; antibody affinity maturation for therapeutic and diagnostic application; and antibody chimerization for cloning and production of variable antibody domain. It also provides Eurofins preclinical services; hybrid service model, a service model designed to reduce time and risk with custom technologies and applications; and breadth and depth to accelerate assay development, screening cascades, drug candidate validation, and new biotherapeutic concepts. The company was incorporated in 1983 and is headquartered in Victoria, Canada.

IPO date 2017-01-03
ISIN CA45257F2008
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета cad
Сайт https://www.ipatherapeutics.com
Цена ао 0.5425
Cambio de precio por día: -1.18% (0.4149)
Cambio de precio por semana.: +2.47% (0.4001)
Cambio de precio por mes: +2.63% (0.3995)
Cambio de precio en 3 meses.: -36.68% (0.6475)
Cambio de precio en seis meses: -59% (1)
Cambio de precio por año: -76.02% (1.71)
Cambio de precio en 3 años.: -92.87% (5.75)
Cambio de precio en 5 años.: -12.77% (0.47)
Cambio de precio en 10 años.: 0% (0.41)
Cambio de precio desde principios de año.: -1.8% (0.4175)

Subestimación

Nombre Significado Calificación
P/S 1.96 7
P/BV 1.41 9
P/E 0 0
EV/EBITDA -2.54 0
Total: 5.25

Eficiencia

Nombre Significado Calificación
ROA, % -39.44 0
ROE, % -59.26 0
Total: 0

Dividendos

Nombre Significado Calificación
Div yield, % 0 0
DSI 0 0
Total: 1.02

Deber

Nombre Significado Calificación
Debt/EBITDA -0.5961 10
Total: 9.6

Impulso de crecimiento

Nombre Significado Calificación
Rentabilidad Revenue, % 74.41 8
Rentabilidad Ebitda, % 6165.75 10
Rentabilidad EPS, % 130.51 10
Total: 9.6



Supervisor Título profesional Pago año de nacimiento
Dr. Jennifer Lynne Bath Ph.D. CEO, President & Non-Independent Director 1.02M
Dr. Ilse Roodink Chief Scientific Officer & Interim General Manager of IPA Europe, Oss 277.03k

DIRECCIÓN: Canada, Victoria, 3204–4464 Markham Street - abrir en mapas de google, abrir mapas de Yandex
Sitio web: https://www.ipatherapeutics.com